► Subscribe to the Financial Times on YouTube: http://bit.ly/FTimeSubs<br /><br />Valeant’s stock has plummeted as critics allege price gouging in the pharma group’s portfolio of generic drugs. Lex’s Robert Armstrong and Jonathan Eley discuss whether the sell-off is overdone.<br /><br /><br />For more video content from the Financial Times, visit http://www.FT.com/video<br /><br /><br />Twitter https://twitter.com/ftvideo<br />Facebook https://www.facebook.com/financialtimes
